Related Experiment Videos
Early clinical experience with subcutaneous GR43175 in acute migraine: an overview
P Tfelt-Hansen1, J Brand, P Dano
1Department of Neurology, University Hospital, Gentofte, Denmark.
Cephalalgia : an International Journal of Headache
|January 1, 1989
Abstract:
In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist. Response rates after 20-30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials. Migraine, treatment, 5-HT agonist, open studies.